First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.

BACKGROUND:Live, attenuated viral vectors that express HIV-1 antigens are being investigated as an approach to generating durable immune responses against HIV-1 in humans. We recently developed a replication-competent, highly attenuated Ad26 vector that expresses mosaic HIV-1 Env (rcAd26.MOS1.HIV-En...

Full description

Bibliographic Details
Main Authors: Kathryn E Stephenson, Michael C Keefer, Catherine A Bunce, Doreen Frances, Peter Abbink, Lori F Maxfield, George H Neubauer, Joseph Nkolola, Lauren Peter, Christopher Lane, Harriet Park, Carl Verlinde, Angela Lombardo, Christopher Yallop, Menzo Havenga, Patricia Fast, John Treanor, Dan H Barouch
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6235250?pdf=render

Internet

http://europepmc.org/articles/PMC6235250?pdf=render

Similar Items